ProQR Therapeutics NV
proqr.comWhat Do They Do?
Develops RNA-editing medicines for people with liver and nervous system diseases, and works with Lilly on RNA-editing drug targets.
20-F for FY2025, filed Mar 12, 2026We are a clinical-stage biotechnology company advancing a pipeline (Figure 1) of RNA editing therapeutics based on our proprietary Axiomer…View ↗
In addition to advancing our wholly-owned pipeline programs, we entered into a global licensing and research collaboration with Eli Lilly…View ↗
Wholly-owned pipeline: We are using our Axiomer platform to develop novel therapies initially for targets related to liver- and…View ↗
Who Are Their Customers?
The company works with Lilly on drug targets and receives research and development funding through collaboration and license agreements.
20-F for FY2025, filed Mar 12, 2026In addition to advancing our wholly-owned pipeline programs, we entered into a global licensing and research collaboration with Eli Lilly…View ↗
The Company entered into collaboration and license agreements in which the Company licenses its intellectual property and/or provides…View ↗
Research and development service feesView ↗
How Are They Changing?
A narrower platform focus
The older report described both Axiomer and Trident RNA platforms and included Trident among the company's earlier-stage technologies. The latest report focuses on Axiomer and its RNA-editing medicines.
20-F for FY2022, filed Mar 29, 2023 20-F for FY2025, filed Mar 12, 2026
Pipeline emphasis moved beyond liver diseases
The older report initially focused its pipeline on liver-originating diseases. The latest report describes programs targeting diseases originating in both the liver and central nervous system, including Rett syndrome.
20-F for FY2022, filed Mar 29, 2023 20-F for FY2025, filed Mar 12, 2026
Loading...
